Description
Ovipol Clio Pharmacodynamics
Estrogen synthesized in the human body. Getting into the bloodstream, it forms a complex with specific receptors (in the uterus, vagina, urethra, breast, liver, hypothalamus, pituitary gland), stimulates the synthesis of DNA and proteins. It has a selective effect, mainly on the cervix, vagina, vulva, causes increased proliferation of vaginal and cervical epithelium, stimulates its blood supply, helps to restore the epithelium in its atrophic changes in the periods of premenopause and menopause, normalizes the pH of the vaginal environment, vaginal microflora, increases the resistance of its epithelium to infectious and inflammatory processes, affects the quality and quantity of cervical mucus. The effect on the endometrium is insignificant (insignificant risk of uterine bleeding). It has a hypolipidemic effect, slightly increases the blood concentration of beta-lipoproteins, increases the sensitivity to the action of insulin, improves glucose utilization, stimulates the production of liver globulins that bind sex hormones, renin, HDL and clotting factors. Owing to its involvement in positive and negative feedback in the hypothalamic-pituitary-ovarian system, estriol is able to cause moderately pronounced central effects; it stimulates parasympathic-mimetic reactions.
Indications
– Hormone replacement therapy for atrophy of the mucous membrane of the lower parts of the urogenital tract, associated with estrogen deficiency;
– Pre- and postoperative therapy in postmenopausal women undergoing or about to undergo vaginal access surgery;
– For diagnostic purposes, with unclear results of a vaginal smear on a background of atrophic changes.
Contraindications
– Established (including history) or suspected breast cancer;
– oestrogen-dependent malignancies or suspected malignancies (including endometrial cancer);
– Undiagnosed genital bleeding;
– Untreated endometrial hyperplasia;
– Thrombosis (venous and arterial) and thromboembolism, current or anamnesis (including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke), cerebrovascular disorders;
– Conditions preceding thrombosis (including transient ischemic attacks, angina pectoris), current or past history;
– Multiple or pronounced risk factors for venous or arterial thrombosis (including complicated heart valve disease, atrial fibrillation, brain or coronary artery disease, uncontrolled arterial hypertension, major surgery with prolonged immobilization, smoking over the age of 35);
– confirmed thrombophilias, hereditary or acquired factors predisposing to the development of venous and arterial thrombosis, such as: resistance to activated protein C, antithrombin III deficiency, protein C deficiency, protein S deficiency, presence of antibodies to phospholipids and others;
– Deep vein thrombophlebitis (including anamnesis);
– Severe hypertriglyceridemia;
– cholestatic jaundice;
– otosclerosis (including previous pregnancy or treatment with sex hormones);
– acute liver disease or a history of liver disease until liver function returns to normal;
– porphyria;
– pregnancy;
– lactation period;
– Hypersensitivity to the components of the drug.
Dosage and administration method
- Intravaginally, before going to bed.
- In atrophy of the mucous membrane of the lower parts of the urogenital tract are prescribed
1 suppository (0.5 mg) daily for the first 2-3 weeks, and then the dose is gradually reduced,
Based on symptoms, 1 suppository (0.5 mg) 2 times a week. - Pre- and postoperative therapy in postmenopausal women – 1 suppository
(0.5 mg) for 2 weeks before or after surgery. - As a diagnostic agent, 1 suppository every other day for a week before the next smear.
- If the next dose of the drug is missed, it should be taken immediately. However, if it is found only on the day of taking the next dose, you should continue taking the drug according to the usual scheme, without making up for the missed dose. Do not use two doses on the same day.
